Vertex Pharmaceuticals VRTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $3.95B— | —— | $3.62B+9.0% | $3.32B+41.8% | ||
| $209.8M+1.3% | $207.2M+14.3% | $181.3M+22.3% | $148.3M+18.1% | ||
| $685.9M-1.8% | $698.5M+20.2% | $581.2M+18.3% | $491.3M+11.3% | ||
| $3.63B+235% | -$2.69B-176% | $3.54B-14.3% | $4.13B+45.3% | ||
| $437.6M+47.0% | $297.7M+48.6% | $200.4M-2.1% | $204.7M-12.9% | ||
| -$945.4M+74.9% | -$3.77B-20.0% | -$3.14B— | —— | ||
| $2.02B+71.4% | $1.18B+175% | $427.6M— | $0-100% | ||
| -$2.26B-51.3% | -$1.49B-158% | -$579.5M— | —— | ||
| $549.8M— | —— | -$1.03B-128% | $3.71B— | ||
| $3.19B+207% | -$2.98B-189% | $3.34B-15.0% | $3.93B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Vertex Pharmaceuticals generate?
- Vertex Pharmaceuticals (VRTX) generated $4.2B in operating cash flow over the trailing twelve months.
- What is Vertex Pharmaceuticals's free cash flow?
- After $530.3M of capital expenditures, Vertex Pharmaceuticals's free cash flow was $3.7B over the trailing twelve months, up 207.9% year over year.
- Where does Vertex Pharmaceuticals's cash flow data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
